Nasdaq Imvt News Today

Immunovant, Inc. (NASDAQ:IMVT – Free Report) – Stock analysts at Zacks Research increased their FY2024 earnings estimates for shares of Immunovant in a research note issued on Thursday, April 25th. Zacks Research analyst E. Bagri now expects that the company will post earnings of ($1.72) per share for the year, up from their prior forecast […]

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) insider Julia G. Butchko sold 10,115 shares of the business’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $29.06, for a total value of $293,941.90. Following the completion of the transaction, the insider now directly owns 451,627 shares in […]

Immunovant, Inc. (NASDAQ:IMVT – Free Report) – Stock analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for Immunovant in a research note issued on Monday, April 8th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings per share of ($0.49) for the quarter, down from their […]

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 9,350,000 shares, an increase of 7.7% from the February 29th total of 8,680,000 shares. Based on an average daily volume of 1,320,000 shares, the […]

Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Truist Financial in a report issued on Monday, Benzinga reports. They presently have a $48.00 price target on the stock. Truist Financial’s price target indicates a potential upside of 47.28% from the stock’s previous close. A number of […]

Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Truist Financial in a report issued on Monday, Benzinga reports. They presently have a $48.00 price target on the stock. Truist Financial’s price objective indicates a potential upside of 47.28% from the stock’s previous close. Several other brokerages have […]

Profund Advisors LLC grew its stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 9.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 49,869 shares of the company’s stock after acquiring an additional 4,115 shares during the quarter. Profund Advisors […]

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) insider Mark S. Levine sold 2,134 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $36.15, for a total transaction of $77,144.10. Following the sale, the insider now owns 301,968 shares in the company, valued […]

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) CFO Eva Renee Barnett sold 2,930 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $36.15, for a total value of $105,919.50. Following the completion of the sale, the chief financial officer now owns […]

JPMorgan Chase & Co. assumed coverage on shares of Immunovant (NASDAQ:IMVT – Free Report) in a research report sent to investors on Tuesday, MarketBeat reports. The brokerage issued an overweight rating and a $51.00 target price on the stock. A number of other research analysts have also recently issued reports on the company. Bank of […]